Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Akari Therapeutics PLC (AKTX : NSDQ)

• Company Description    Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $1.09 Daily Weekly Monthly 20 Day Moving Average: 55,379 shares Shares Outstanding: 59.35 (millions) Market Capitalization: $64.69 (millions) Beta: 1.24 52 Week High: $1.89 52 Week Low: $1.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.63% 4.04% 12 Week -11.38% -2.57% Year To Date -27.33% -11.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 75/76 WIMPOLE STREET - LONDON,X0 W1G 9RT GBR ph: 44-20-8004-0270 fax: 646-843-9352 info@akaritx.com http://www.akaritx.com

• General Corporate Information    Officers Clive Richardson - Chief Executive Officer and Chief Operating Office Ray Prudo - Executive Chairman Torsten Hombeck - Chief Financial Officer James Hill - Director Stuart Ungar - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00972G108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/21 Next Expected EPS Date: 07/05/22 Share - Related Items Shares Outstanding: 59.35 Most Recent Split Date: 9.00 (0.10:1) Beta: 1.24 Market Capitalization: $64.69 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/05/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 10.19 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 45.45% vs. Previous Quarter: -300.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - -281.03 ROA 03/31/22 - - 12/31/21 - - 09/30/21 - -175.82 Current Ratio 03/31/22 - - 12/31/21 - - 09/30/21 - 4.38 Quick Ratio 03/31/22 - - 12/31/21 - - 09/30/21 - 4.38 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - - 09/30/21 - 0.24 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - 0.00

Powered by Zacks Investment Research ©